Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903132 · ClinicalTrials.gov registry record
Cellular Senescence and COVID-19 Long-Hauler Syndrome
A clinical trial of SARS-CoV2 Infection, sponsored by Mayo Clinic.
- Active
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT04903132 is a study of SARS-CoV2 Infection that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 200 participants, below the 1,224-participant average among 6 other SARS-CoV2 Infection trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04903132, a study of SARS-CoV2 Infection, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04903132
The ClinicalTrials.gov registry entry for NCT04903132 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,224-participant average among 6 other SARS-CoV2 Infection trials with a reported enrollment target (84% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV2 Infection appearing as the primary indexed condition, and to 0 interventions.
NCT04903132 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04903132 about?
NCT04903132 is a clinical study titled "Cellular Senescence and COVID-19 Long-Hauler Syndrome". The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.
What is the current status of trial NCT04903132?
This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2021-03-01. Estimated completion is 2026-12.
What conditions does trial NCT04903132 study?
This clinical trial studies the following conditions: SARS-CoV2 Infection.
Who is sponsoring clinical trial NCT04903132?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04903132 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Pediatric COVID Outcomes Study (PECOS)
ACTIVE NOT RECRUITING
-
Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake
COMPLETED · NA
-
TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood
COMPLETED
-
A Retrospective Study of COVID-19 Treatments
COMPLETED
-
COVID-19 SARS-CoV-2 RAST Study
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.